Tafamidis meglumine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330120

CAS#: 951395-08-7 (meglumine)

Description: Tafamidis, also known as Fx-1006 or PF-06291826, is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein.

Chemical Structure

Tafamidis meglumine
CAS# 951395-08-7 (meglumine)

Theoretical Analysis

MedKoo Cat#: 330120
Name: Tafamidis meglumine
CAS#: 951395-08-7 (meglumine)
Chemical Formula: C21H24Cl2N2O8
Exact Mass: 502.09
Molecular Weight: 503.329
Elemental Analysis: C, 50.11; H, 4.81; Cl, 14.09; N, 5.57; O, 25.43

Price and Availability

Size Price Availability Quantity
1g USD 2350 2 Weeks
2g USD 3950 2 Weeks
500mg USD 1350 2 Weeks
200mg USD 750 2 Weeks
100mg USD 450 2 Weeks
50mg USD 250 2 Weeks
Bulk inquiry

Related CAS #: 594839-88-0 (free acid), 951395-08-7 (meglumine),

Synonym: Tafamidis meglumine; Fx 1006A; Fx-1006A; Fx1006A; PF-06291826; PF 06291826; PF06291826;

IUPAC/Chemical Name: (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid


InChi Code: InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

SMILES Code: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC.O=C(C1=CC=C2N=C(C3=CC(Cl)=CC(Cl)=C3)OC2=C1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Preparing Stock Solutions

The following data is based on the product molecular weight 503.329000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Cruz MW. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clin Auton Res. 2019 Sep;29(Suppl 1):19-24. doi: 10.1007/s10286-019-00625-9. Epub 2019 Aug 12. Review. PubMed PMID: 31407119; PubMed Central PMCID: PMC6763524. 2: Lamb YN, Deeks ED. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs. 2019 Jun;79(8):863-874. doi: 10.1007/s40265-019-01129-6. Review. PubMed PMID: 31098895. 3: Lorenzini M, Elliott PM. Tafamidis for the treatment of transthyretin amyloidosis. Future Cardiol. 2019 Mar;15(2):53-61. doi: 10.2217/fca-2018-0078. Epub 2019 Feb 15. Review. PubMed PMID: 30767672. 4: Planté-Bordeneuve V, Lin H, Gollob J, Agarwal S, Betts M, Fahrbach K, Chitnis M, Polydefkis M. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother. 2019 Mar;20(4):473-481. doi: 10.1080/14656566.2018.1554648. Epub 2018 Dec 12. Review. PubMed PMID: 30489166. 5: Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circ Heart Fail. 2017 Jun;10(6). pii: e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815. Review. PubMed PMID: 28611125. 6: Institute for Quality and Efficiency in Health Care. Tafamidis Meglumine -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2012 Mar 13. Available from http://www.ncbi.nlm.nih.gov/books/NBK385651/ PubMed PMID: 27905733. 7: Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. Review. PubMed PMID: 26894299; PubMed Central PMCID: PMC4919130. 8: Scott LJ. Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs. 2014 Aug;74(12):1371-8. doi: 10.1007/s40265-014-0260-2. Review. PubMed PMID: 25022953. 9: Buxbaum JN. Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy. Degener Neurol Neuromuscul Dis. 2012 Oct 19;2:165-173. doi: 10.2147/DNND.S24624. eCollection 2012. Review. PubMed PMID: 30890886; PubMed Central PMCID: PMC6065585. 10: de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today (Barc). 2012 May;48(5):331-7. doi: 10.1358/dot.2012.48.5.1808486. Review. PubMed PMID: 22645721.